MSI-H status in advanced G/GEJ
Kohei Shitara, MD, National Cancer Center Hospital, Kashiwa, Japan, outlines the importance of microsatellite instability-high (MSI-H) status in the treatment…
Related Articles
Improving early clinical trial enrolment in pediatric oncology
Lesleigh Abbott, MD, The Children’s Hospital of Eastern Ontario, Ottawa, Canada, gives an overview of barriers to early-phase clinical trial enrolment for pediatric patients with…
Reforming the treatment landscape in melanoma with T-cell therapies
Martin Wermke, MD, TU Dresden University of Technology, Dresden, Germany, shares his insight into the emerging T-cell therapies for patients with melanoma and their impact…
Evaluating fianlimab and cemiplimab in PD-L1+ recurrent/metastatic HNSCC
Danny Rischin, MD, Peter MacCallum Cancer Centre, Melbourne, Australia, describes the design of a Phase II trial (NCT06769698) of fianlimab plus cemiplimab versus cemiplimab plus…
Important considerations in developing CAR-T cell therapy for GBM
Reena Thomas, MD, PhD, Stanford University, Stanford, CA, comments on the importance of managing on-target tumor-associated inflammatory neurologic impacts in patients with glioblastoma (GBM). The…
How will ctDNA and liquid biopsies be utilized in gynecological cancers?
Jyoti Mayadev, MD, University of California San Diego Medical Center, San Diego, CA, discusses the emerging developments in liquid biopsies and circulating tumor DNA (ctDNA)…
Welcome! You are invited to join a webinar: Post-ASCO 2025 Skin Cancer Highlights. After registering, you will receive a confirmation email about joining the webinar.
Virtual webinar hosted by VJOncology featuring presentations & discussions on selected abstracts in skin cancer from ASCO 2025. Chaired by Dr Meredith McKean Moderated by…
Post-ASCO 2025 Breast Cancer Highlights Archives – VJOncology
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our…
AI model predicts claudin 18.2 and immune phenotype in gastric cancer
Hyung-Don Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, comments on an artificial intelligence (AI) model developed to predict claudin 18.2 expression and immune…
RELATIVITY-020: dose comparison of nivolumab and relatlimab in melanoma
Georgina Long, PhD, MBBS, FRACP, FAHMS, University of Sydney, Sydney, Australia, discusses findings from cohort E of the Phase I/IIa RELATIVITY-020 trial (NCT01968109), which assessed…
ARCHES: 5-year OS analysis of enzalutamide plus ADT in mHSPC
Andrew Armstrong, MD, MS, Duke Cancer Institute, Durham, NC, discusses the 5-year overall survival (OS) analysis from the Phase III ARCHES trial (NCT02677896) of enzalutamide…